• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Sema4 Holdings Corp (NQ: SMFR )

    N/A UNCHANGED
    Last Price Updated: 4:00 PM EST, Jan 9, 2023 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Sema4 Holdings Corp

    < Previous 1 2 3 4 5 Next >
    Sema4 Holdings Corp. (NASDAQ: SMFR) Long Term Shareholder Notice: Investigation of Potential Wrongdoing
    San Diego, CA -- (SBWIRE) -- 02/08/2023 -- An investigation was announced for current long-term investors in shares of Sema4 Holdings Corp. (NASDAQ: SMFR) concerning potential breaches of fiduciary... 
    Via SBWire
    Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Gainers CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash. 
    Via Benzinga
    Sema4 Announces Name Change to GeneDx and Provides Preliminary 2022 Financial Results and 2023 Guidance
    From GeneDx Holdings Corp.
    Via GlobeNewswire
    Sema4 Holdings's Return on Invested Capital Overview
    Via Benzinga
    What To Know About Goldman Sachs's Downgrade of Sema4 Holdings
    Via Benzinga
    Sema4|GeneDx to Participate in the 41st Annual J.P. Morgan Healthcare Conference
    Sema4|GeneDx President & Chief Executive Officer, Katherine Stueland, to deliver presentation 
    From Sema4
    Via GlobeNewswire
    Stocks That Hit 52-Week Lows On Thursday
      On Thursday, 116 companies set new 52-week lows. 
    Via Benzinga
    Stocks That Hit 52-Week Lows On Monday
      Monday saw 196 companies set new 52-week lows. 
    Via Benzinga
    Stocks That Hit 52-Week Lows On Friday
      On Friday, 127 companies set new 52-week lows. 
    Via Benzinga
    ConocoPhillips To Rally Over 30%? Here Are 10 Other Price Target Changes For Wednesday
    Barclays raised ConocoPhillips (NYSE: COP) price target from $135 to $151. Barclays analyst Jeanine Wai maintained an Overweight rating on the stock. ConocoPhillips shares fell 3.2% to close at $115.61... 
    Via Benzinga
    New Research from Sema4|GeneDx Highlights the Importance of Rapid Exome Sequencing for Diagnosing Mitochondrial Diseases in the NICU
    Data underscores the value of mitochondrial DNA testing and the opportunity to improve health outcomes for critically ill newborns with early medical intervention 
    From Sema4
    Via GlobeNewswire
    Sema4 Reports Third Quarter 2022 Financial Results and New Strategic Direction
    From Sema4
    Via GlobeNewswire
    Stocks That Hit 52-Week Lows On Friday
      On Friday, 72 companies hit new 52-week lows. 
    Via Benzinga
    NASDAQ:SMFR Investor Alert: Deadline on November 7, 2022 in Lawsuit Against Sema4 Holdings Corp.
    San Diego, CA -- (SBWIRE) -- 11/09/2022 -- The Shareholders Foundation announced that a deadline is coming up on November 7, 2022 in the lawsuit filed for certain investors of Sema4 Holdings Corp.... 
    Via SBWire
    Deadline Alert: Sema4 Holdings Corp. (SMFR, SMFRW) Class Action - Bronstein, Gewirtz & Grossman, LLC, A Prominent Firm, Encourages Shareholders of Last Few Hours to Actively Participate
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    Stocks That Hit 52-Week Lows On Wednesday
      During Wednesday's session, 107 stocks hit new 52-week lows. 
    Via Benzinga
    Why Foresight Autonomous Shares Jumped 33%; Here Are 83 Biggest Movers From Yesterday
    Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares surged 106.3% to close at $0.21 on Wednesday after dipping around 48% on Tuesday. Fast Radius established a timeline for a Chapter 11 sale process. 
    Via Benzinga
    Stocks That Hit 52-Week Lows On Wednesday
      On Wednesday, 70 companies set new 52-week lows. 
    Via Benzinga
    SMFR FINAL DEADLINE TODAY: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Sema4 Holdings Corp. Investors to Secure Counsel Before Important November 7 Deadline in Securities Class Action - SMFR, SMFRW
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Topics Lawsuit
    Exposures Financial Legal
    Earnings Scheduled For November 14, 2022
    Companies Reporting Before The Bell • Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million. 
    Via Benzinga
    Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bed Bath & Beyond, Sema4, Medtronic, and Palantir and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    SMFR FINAL DEADLINE TOMORROW: ROSEN, LEADING INVESTOR COUNSEL, Encourages Sema4 Holdings Corp. Investors to Secure Counsel Before Important November 7 Deadline in Securities Class Action - SMFR, SMFRW
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Topics Lawsuit
    Exposures Financial Legal
    SEMA4 HOLDINGS 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Sema4 Holdings Corp. - SMFR
    From Kahn Swick & Foti, LLC
    Via Business Wire
    Sema4 to Report Third Quarter 2022 Financial Results on Monday, November 14th, 2022
    From Sema4
    Via GlobeNewswire
    Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Kohl’s, Bed Bath & Beyond, Sema4, and Medtronic and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Sema4|GeneDx Commends New Evidence-Based Guidelines from the National Society of Genetic Counselors Recommending Exome Sequencing as a First-Tier Genetic Test for Unexplained Epilepsies
    Guideline adoption can help end the diagnostic odyssey experienced by many families 
    From Sema4
    Via GlobeNewswire
    ROSEN, A TOP RANKED FIRM, Encourages Sema4 Holdings Corp. Investors With Losses Over $100K to Secure Counsel Before Important November 7 Deadline in Securities Class Action - SMFR, SMFRW
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Topics Lawsuit
    Exposures Financial Legal
    Sema4|GeneDx Announces Results from Phase 1 of SeqFirst Study, Demonstrating Broad Utility of Rapid Whole Genome Sequencing for Critically Ill Newborns
    From Sema4
    Via GlobeNewswire
    Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Kohl’s, Bed Bath & Beyond, Sema4, and Medtronic and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Sema4|GeneDx collaborates on new research demonstrating genome and exome sequencing deliver more diagnostic certainty than multi-gene panels
    Exome and genome tests report 30% fewer inconclusive results and a higher diagnostic yield compared to multi-gene panel tests; research to be presented at American Society of Human Genetics Annual... 
    From Sema4
    Via GlobeNewswire
    < Previous 1 2 3 4 5 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.